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Purpose: The purpose of this study was to compare the efficacy of rifampin-bonded gelatin-sealed and silver acetate/
collagen-coated knitted polyester prostheses for the prevention of bacteremic graft infection in an animal model.
Methods: Eighteen 6.0-mm polyester grafts (length, 5.0 cm) were implanted in dogs end-to-end into the infrarenal aorta.
The dogs were divided into four groups as a function of type of prosthesis implanted. The dogs in groups I (n  3) and
II (n  3) received control gelatin-sealed or collagen-coated polyester prostheses, respectively. In group III (n  6), the
dogs received rifampin-bonded gelatin-sealed polyester prostheses. In group IV (n  6), the dogs received silver/
collagen-coated polyester prostheses. Two days after implantation, the grafts were challenged with 6 109 Staphylococcus
aureus intravenously. One week after implantation, the grafts were harvested with sterile technique. Quantitative cultures
were obtained from all the harvested grafts. The results were expressed as colony-forming units per cm2 of graft material.
Bacteriologic study was also performed on various tissue samples. The 2 test was used to compare the culture proven
infection of control and antimicrobial grafts.
Results: All the control grafts were infected with S aureus at the time of removal. Five of the six silver/collagen-coated
grafts were infected, whereas none of the six rifampin-bonded gelatin-sealed grafts grew S aureus (P < .01). There was no
significant difference in the number of positive culture results of organ samples between the different groups of dogs.
Conclusion: These results indicate that rifampin-bonded gelatin-sealed polyester grafts are significantly more resistant to
bacteremic infection than are silver/collagen-coated polyester grafts in a highly challenging model. (J Vasc Surg 2002;
35:1260-3.)
Despite refinements in graft fabrication, implantation
techniques, and routine antibioprophylaxis, vascular pros-
thetic infections remain a serious complication of recon-
structive vascular surgery. Graft infection is always difficult
to eradicate and, if not recognized or adequately treated,
eventually causes prosthesis failure, hemorrhage, or sepsis.
Even in experienced centers and in recent series, mortality
and amputation rates associated with infected grafts remain
significant.1-5
Our laboratory has had a long interest in the develop-
ment of a prosthesis resistant to infection. The introduction
of sealed grafts has enabled the use of the sealant as an
antibiotic bonding carrier. In previous studies, we showed
the efficacy of rifampin-bonded gelatin-sealed polyester
prostheses in the prevention of bacteremic graft infection6
and in the treatment of aortic graft infections with in situ
replacement.7 We also showed the efficacy of rifampin-
bonded prostheses in the prevention of graft reinfection
after in situ replacement of a prosthesis infected by a highly
rifampin resistant Staphylococcus epidermidis.8
More recently, silver-coated knitted polyester prosthe-
ses have been proposed as an alternative for prevention or
treatment of prosthetic graft infections. The purpose of this
experimental study was to compare the efficacy of rifampin-
bonded gelatin-sealed knitted and silver-coated polyester
prostheses in resisting infection after a bacteremic challenge.
MATERIALS AND METHODS
Protocol. The infrarenal aortas of 18 dogs were re-
placed with four types of prostheses. In groups I and II (n
3 in each group), the animals received a conventional sealed
knitted polyester prosthesis. In groups III and IV, the
animals received a rifampin-bonded (n  6) or a silver-
coated (n 6) knitted polyester prosthesis. Two days after
implantation, a bacteremia was produced with an intrave-
nous injection of 109 S aureus. One week after implanta-
tion, the prostheses were removed and submitted to quan-
titative bacteriologic studies.
Materials. Four types of vascular prostheses were used
in this study: collagen-coated knitted polyester prostheses
(Intergard, InterVascular, La Ciotat, France), silver ace-
tate/collagen-coated knitted polyester prostheses (Inter-
gard Silver, InterVascular), gelatin-sealed knitted polyester
prostheses (Gelsoft Plus, Sulzer Vascutek, Inchinnan, Scot-
land), and the same gelatin-sealed prostheses soaked in
rifampin (60 mg/L; gelatin-sealed rifampin-bonded
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grafts). All the grafts were 6 mm-diameter tubes. Rifampin
was Rifadine (Laboratoires Roussel Diamant, Paris, France).
Implantation of prostheses. Eighteen female mon-
grel dogs that weighed 12 to 20 kg underwent anesthesia
with intravenous injection of pentobarbital at a dose of 30
mg/kg and were mechanically ventilated. Hydration was
maintained with continuous infusion of Ringer’s lactate at
the rate of 15 mL/kg/h. After the dogs were placed in
dorsal decubitus position, laparotomy was performed with
sterile surgical conditions and a 3-cm to 4-cm segment of
the infrarenal abdominal aorta was exposed. The lumbar
and the inferior mesenteric arteries were ligated and sec-
tioned to allow better mobilization of the exposed arterial
segment. After intravenous administration of a 0.5 mg/kg
bolus of heparin, the aorta was clamped just below the renal
arteries and at its end. A 5-mm to 8-mm aortic segment
then was removed. Resection resulted in a 30-mm to
40-mm gap after elastic recoil of the sectioned artery. The
prosthesis was implanted with two end-to-end anastomoses
with the use of 6-0 polypropylene sutures. After the anas-
tomoses were completed and hemostasis checked, the pros-
thesis was covered with direct closure of the posterior
parietal peritoneum. The abdominal wall was closed in
layers with a standard surgical technique. Mechanical ven-
tilation was maintained until awakening. Dogs did not
receive perioperative antibiotic prophylaxis. All animals re-
ceived humane care in compliance with the Principles of
Laboratory Animal Care and Guide for the Care and Use of
Laboratory Animals. The dogs were placed in individual
cages and examined daily.
Bacterial strain and bacteremic challenge. The bac-
terial strain used in this study was S aureus A980142, from
the French National Reference Center. S aureus A980142
is sensitive to rifampin but resistant to methicillin (hetero-
geneous type). Bacteria were stored at 20° C. When
necessary, the strain was plated on trypticase soy agar (TSA)
for 18 hours at 37° C. Four colonies then were transferred
with a sterile loop to 40 mL of trypticase soy broth and
incubated for 18 hours at 37° C. The resulting suspension
was centrifuged (10 minutes, 3000 rpm), and the pellet was
resuspended in 4 mL of normal saline solution. This ob-
tained suspension was the inoculating solution. The num-
ber of viable organisms in the inoculating solution was
verified with backplating on TSA. Forty-eight hours after
graft implantation, transient bacteremia was produced in
the dogs with intravenous injection of 1 mL S aureus
suspension over a period of 1 minute.
Explantation of prostheses. The animals were killed
5 days after the bacteremic challenge. Death was performed
with sterile surgical conditions after anesthetization as pre-
viously described. Macroscopic signs of infection were
noted. In addition to the prosthesis, samples for bacterio-
logic studies were collected from various organs (liver,
spleen, left kidney, and lung).
Bacteriologic studies. Explanted prostheses were
split lengthwise to facilitate the extraction of bacteria. The
whole prosthesis was placed in a sterile mortar with 2 mL of
saline solution and hand-crushed for 2 minutes. One mil-
liliter of the crushing effluent and 0.1 mL aliquots of serial
dilutions ranging from 101 to 104 were cultured on
TSA. Dishes were incubated at 37° C with aerobic condi-
tions for 48 hours. Colony counts were estimated in colo-
ny-forming units (CFU) and then extrapolated to the 2-mL
initial suspension. Final quantitative estimation of contam-
ination on the surface of the prosthesis was expressed as the
number of CFU/cm2.
The tissue specimens were placed in trypticase soy
broth supplemented with glucose and incubated for as
much as 7 days at 37° C. Broth content was vortexed and
placed on TSA. Plates were incubated at 37° C with aerobic
conditions for 48 hours. Broth culture results were classi-
fied as positive if the study strain of S aureus was recovered.
Statistical analysis. The number of culture positive
infected grafts observed in the different groups were com-
pared with the 2 test. Statistical significance was assigned
when P values were less than .05.
RESULTS
The actual inoculum size (mean  standard deviation)
was 6.3  2.8  109 CFU/mL, without significant differ-
ences between the four groups of dogs. One dog in group
IV died 3 days after bacterial infusion with evidence of graft
infection at autopsy and was included in further analysis. All
the grafts were patent at the time of explantation. Macro-
scopic signs of infection were observed with all control
grafts and with five of the silver-coated grafts. All the
control grafts were infected with S aureus. Five of the six
silver/collagen-coated grafts in group IV were infected
with S aureus. None of the gelatin-sealed rifampin-bonded
grafts (0/6) grew bacteria (Table I). This difference was
statistically significant (P  .01) when compared with the
control groups and the silver-coated group. Bacteriologic
study results on samples taken from organs were positive in
four of 12 samples in group I, in five of 12 samples in group
II, in seven of 24 samples in group III, and in nine of 24
samples in group IV, without statistically significant differ-
ence (Table II).
DISCUSSION
This experimental study confirms the efficacy of ri-
fampin-bonded gelatin-sealed prostheses and shows the
inability of silver/collagen-coated prostheses to resist infec-
tion from S aureus bacteremia. In view of the increasing
bacterial resistance to antibiotics, silver coating was an
appealing concept for the prevention of graft infections.
Different forms of silver molecules have been bonded to a
large variety of medical devices, including central vascular,9
urinary,10 and peritoneal catheters,11 prosthetic heart valve
sewing rings,12 sutures,13 fracture fixation devices,14 and
vascular prostheses.15,16 Despite their large number, the
antiinfective activity of these silver-coated medical devices
has not been collectively addressed. Even when they
showed an antimicrobial activity in vitro, implanted medi-
cal prostheses that were coated with silver alone have not
been proven to be infection-resistant in most clinical stud-
ies. Randomized clinical studies that show the efficacy of
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silver-coated prostheses are rare and have dealt with small
numbers of patients or are controversial. The differences
observed between in vitro experiments and clinical studies
can be the consequence of minimal leaching or nonleach-
ing silver-coated surfaces and limitations caused by poten-
tial silver toxicity.17 Different techniques have been used to
incorporate silver alone onto the surface of prostheses.
When the adherence of silver molecules is tight, as observed
in silver-coated prosthetic heart valve sewing rings, despite
the durability of the antimicrobial surface, the minimal
leaching of silver off the device may be a disadvantage, with
small zones of bacterial inhibition around the coated mate-
rial in vitro and a limited clinical efficacy.18,19 When the
technique used to incorporate silver onto the surface of a
prosthesis allows leaching of silver off the surface or when
the silver is complexed with antibiotics or other antimicro-
bial agents, larger zones of inhibition are obtained and a
better clinical antimicrobial efficacy can be expected.
Silver ions are active against a broad spectrum of bac-
teria, and their antibacterial activity is proportional to their
concentration. On the contrary, metallic silver has only
slight antibacterial efficacy because of its chemical stability.
Silver ions, often released from inorganic silver salts, act by
displacing other essential metal ions such as Ca2 or Zn.
The binding of silver ions to the bacterial DNA interacts
with cellular oxidation processes and inhibits the respiratory
chain. This activity is proportional to the silver ion concentra-
tion, and the minimum inhibitory concentration of silver to
staphylococci is between 0.5 mg/L and 10 mg/L. Pseudomo-
nas species are more susceptible to silver ions than are staph-
ylococci.20 Bactericidal effect is achieved through silver-DNA-
chelate complexes. Nevertheless, the biologic environment
may influence and decrease the antimicrobial activity of silver
ions. In particular, blood proteins deposited onto the surface
of implants, such as albumin, may bind silver ions that no
longer have antimicrobial activity.21 In addition, the conver-
sion of silver acetate to silver chloride in the presence of the
high chloride ion content of the body will also reduce the
availability of silver ions. Although silver acetate is fairly solu-
ble in water (1.02 gm/100 mL), silver chloride is almost
insoluble (0.000089 gm/100 mL).22 These factors may have
contributed to the lack of antimicrobial efficacy of the silver
acetate added to the collagen coating of the prostheses im-
planted in dogs of group IV.
The efficacy of complexing silver with antibiotics on the
surface of polytetrafluoroethylene grafts has also been eval-
uated in several studies.15,16,23 The complexing of silver
and norfloxacin increased the antibacterial activity of poly-
tetrafluoroethylene grafts compared with grafts coated with
norfloxacin alone and offered significant protection against
infection from local bacterial contamination in a dog mod-
el.23 In another in vivo experimental study, a complex of
silver and ciprofloxacin increased the elution and prolonged
the duration of ciprofloxacin release from the coated poly-
tetrafluoroethylene compared with grafts coated with cip-
rofloxacin alone.15 In a dog model of S aureus infection of
aortic polytetrafluoroethylene grafts, the mean number of
bacteria retrieved from grafts coated with silver and oxacil-
lin or silver and amikacin was significantly lower than that
observed with uncoated grafts.16 In these experiments, the
large zones of inhibition measured in vitro with the silver-
antibiotic coated grafts suggested that the antibiotic is
largely responsible for the antimicrobial efficacy in vivo.
The potential toxicity of silver-containing medical de-
vices suggests the use of other techniques to bind antimi-
crobial agents onto vascular prostheses, and many experi-
mental studies have shown the efficacy of antibiotic-
bonded grafts to reduce the incidence rate of graft
infection.24 The advent of protein-sealed polyester pros-
theses has raised the possibility of the sealant as a vehicle for
antibiotic delivery. However, an infection-resistant pros-
thesis should comply with the following prerequisites. First,
the antimicrobial agent bonded to the prosthesis should
have a bactericidal effect against the bacteria involved in
graft infections. Second, it should be nonallergenic and
have a minimal risk of toxicity. Third, the duration of the
antibacterial activity of the bonded graft should be as long
as possible to allow a satisfactory healing without infection.
Table I. Bacteriologic evaluation of prostheses
Infected
grafts
Viable counts of infected grafts,
median (range) (CFU/cm2)
Group I
Control gelatin-sealed grafts 3/3 2 (2-75  100)
Group II
Control collagen-coated grafts 3/3 12 (5  100-9.9  105)
Group III
Gelatin-sealed rifampin-bonded grafts 0/6 —
Group IV
Silver/collagen-coated grafts 5/6* 4.1  103 (2.5  103-5.6  103)
*P  .01 versus gelatin-sealed rifampin-bonded prostheses.
Table II. Bacteriologic study of organ samples
No. with positive culture/total number examined
Kidney Lung Spleen Liver All samples
Group I 0/3 1/3 2/3 1/3 4/12
Group II 1/3 2/3 0/3 2/3 5/12
Group III 2/6 2/6 1/6 2/6 7/24
Group IV 2/6 2/6 3/6 2/6 9/24
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Finally, the technique used to bind the antimicrobial agent
should be easy to accomplish in the usual clinical setting.
With consideration of these prerequisites, rifampin was
a good candidate for bonding, with a strong affinity for
gelatin-sealed polyester grafts.25 Rifampin shows a wide
antibacterial activity against most aerobic gram-positive
cocci, notably with remarkable antistaphylococcal potency,
and against many aerobic gram-negative organisms that
cause vascular graft infection. It is, overall, a well-tolerated
drug, especially after the parenteral administration of a
single dose slowly released in the bloodstream. With a dog
model of bacteremia, we showed the resistance of thoraco-
abdominal aortic rifampin-bonded grafts to an early post-
operative methicillin resistant S aureus bacteremia.6 These
experimental results were the rationale for a prospective
randomized trial that evaluated the efficacy of rifampin in
the prevention of early wound and graft infection after
prosthetic aortoiliofemoral reconstruction. In this trial,
conducted in 2610 patients in 90 centers, the incidence rate
of wound infection was significantly reduced in patients
who received a rifampin-bonded graft in association with
perioperative systemic antibioprophylaxis.26
Rifampin-bonded grafts may also be a promising alter-
native for in situ replacement of infected grafts. With the
use of a dog model, we showed that rifampin-bonded
gelatin-sealed grafts were resistant to infection when used
for in situ replacement of a graft infected with S epidermi-
dis.7 Because of the high local concentrations of rifampin
obtained with this technique, we also recently showed its
efficacy when the challenging S epidermidis was resistant to
rifampin.8 Early clinical results observed after in situ re-
placement of infected grafts with rifampin-bonded polyes-
ter appear favorable,27-29 which justifies further investiga-
tions of antibiotic-bonded vascular prostheses.
In conclusion, silver acetate does not appear to afford
knitted collagen-coated polyester prostheses a significant
antimicrobial activity in vivo. Rifampin soaking of gelatin-
coated prostheses is a simple technique that has been shown
to be highly effective in vivo and that can be used in patients
at risk of infection.
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